You are here

Dehydroepiandrosterone Combination Receives FDA Orphan Drug Status

Montreal, Canada, August 29, 2003 - Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, announced today that it has received orphan drug designation for Fidelin™ (dehydroepiandrosterone / prasterone / DHEA) for adrenal insufficiency from the U.S. Food and Drug Administration (FDA). Fidelin™ was granted orphan drug designation in Europe earlier this month.

The FDA’s orphan drug program is intended to encourage research, development and approval of products for diseases that affect fewer than 200,000 patients in the United States. Orphan drug designation will provide Fidelin™ with seven years of market exclusivity following regulatory approval.

Paladin acquired the development and marketing rights to DHEA in 1999 through its acquisition of Neuroscience Pharma Inc., a company focused on the discovery and development of novel therapeutics relating to DHEA. Paladin is continuing the development of this product for adrenal insufficiency, a rare chronic condition brought about by failure of the adrenal glands, which affects an estimated 100,000 patients in the U.S. Current standard therapies frequently fail to restore full well being, and as such, patients with this disorder continue to suffer from a diminished quality of life.

"The FDA’s decision follows in close succession to our recent orphan drug designation for Fidelin™ in Europe,” said Dr. Tom Koutsavlis, MD, MSc, Vice President of Scientific Affairs at Paladin. “The combination of orphan drug designations for Fidelin™ in both Europe and the United States supports our continued investment in developing this novel and effective therapy for adrenal insufficiency."

Source: Paladin Labs Inc.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs